Cancer Epidemiology最新文献

Evaluating the quality of prostate cancer diagnosis recording in CPRD GOLD and CPRD Aurum primary care databases for observational research: A study using linked English electronic health records

IF 2.4 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2024-11-30 DOI: 10.1016/j.canep.2024.102715

Gayasha Somathilake , Elizabeth Ford , Jo Armes , Sotiris Moschoyiannis , Michelle Collins , Patrick Francsics , Agnieszka Lemanska

Background

Primary care data in the UK are widely used for cancer research, but the reliability of recording key events like diagnoses remains uncertain. Although data linkage can improve reliability, its costs, time requirements, and sample size constraints may discourage its use. We evaluated accuracy, completeness, and date concordance of prostate cancer (PCa) diagnosis recording in Clinical Practice Research Datalink (CPRD) GOLD and Aurum compared to linked Cancer Registry (CR) and Hospital Episode Statistics (HES) Admitted Patient Care (APC) in England.

Methods

Incident PCa diagnoses (2000–2016) for males aged ≥46 at diagnosis who remained registered with their General Practitioner (GP) by age 65 and were recorded in at least one data source were analysed. Accuracy was the proportion of diagnoses recorded in GOLD or Aurum with a corresponding record in CR or HES. Completeness was the proportion of CR or HES diagnoses with a corresponding record in GOLD or Aurum.

Results

The final cohorts for comparisons included 29,500 records for GOLD and 26,475 for Aurum. Compared to CR, GOLD was 86 % accurate and 65 % complete, while Aurum was 87 % accurate and 77 % complete. Compared to HES, GOLD was 76 % accurate and 60 % complete, and Aurum was 79 % accurate and 70 % complete. Concordance in diagnosis dates improved over time in both GOLD and Aurum, with 93 % of diagnoses recorded within a year compared to CR, and 66 % (GOLD) and 71 % (Aurum) compared to HES. Delays of 2–3 weeks in primary care diagnosis recording were observed compared to CR, whereas most diagnoses appeared at least 3 months earlier in primary care than in HES.

Conclusions

Aurum demonstrated better accuracy and completeness for PCa diagnosis recording than GOLD. However, linkage to HES or CR is recommended for improved case capture. Researchers should address the limitations of each data source to ensure research validity.

{"title":"Evaluating the quality of prostate cancer diagnosis recording in CPRD GOLD and CPRD Aurum primary care databases for observational research: A study using linked English electronic health records","authors":"Gayasha Somathilake , Elizabeth Ford , Jo Armes , Sotiris Moschoyiannis , Michelle Collins , Patrick Francsics , Agnieszka Lemanska","doi":"10.1016/j.canep.2024.102715","DOIUrl":"10.1016/j.canep.2024.102715","url":null,"abstract":"<div><h3>Background</h3><div>Primary care data in the UK are widely used for cancer research, but the reliability of recording key events like diagnoses remains uncertain. Although data linkage can improve reliability, its costs, time requirements, and sample size constraints may discourage its use. We evaluated accuracy, completeness, and date concordance of prostate cancer (PCa) diagnosis recording in Clinical Practice Research Datalink (CPRD) GOLD and Aurum compared to linked Cancer Registry (CR) and Hospital Episode Statistics (HES) Admitted Patient Care (APC) in England.</div></div><div><h3>Methods</h3><div>Incident PCa diagnoses (2000–2016) for males aged ≥46 at diagnosis who remained registered with their General Practitioner (GP) by age 65 and were recorded in at least one data source were analysed. Accuracy was the proportion of diagnoses recorded in GOLD or Aurum with a corresponding record in CR or HES. Completeness was the proportion of CR or HES diagnoses with a corresponding record in GOLD or Aurum.</div></div><div><h3>Results</h3><div>The final cohorts for comparisons included 29,500 records for GOLD and 26,475 for Aurum. Compared to CR, GOLD was 86 % accurate and 65 % complete, while Aurum was 87 % accurate and 77 % complete. Compared to HES, GOLD was 76 % accurate and 60 % complete, and Aurum was 79 % accurate and 70 % complete. Concordance in diagnosis dates improved over time in both GOLD and Aurum, with 93 % of diagnoses recorded within a year compared to CR, and 66 % (GOLD) and 71 % (Aurum) compared to HES. Delays of 2–3 weeks in primary care diagnosis recording were observed compared to CR, whereas most diagnoses appeared at least 3 months earlier in primary care than in HES.</div></div><div><h3>Conclusions</h3><div>Aurum demonstrated better accuracy and completeness for PCa diagnosis recording than GOLD. However, linkage to HES or CR is recommended for improved case capture. Researchers should address the limitations of each data source to ensure research validity.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102715"},"PeriodicalIF":2.4,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142743281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differences in recording of cancer diagnosis between datasets in England: A population-based study of linked cancer registration, hospital, and primary care data

IF 2.4 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2024-11-29 DOI: 10.1016/j.canep.2024.102703

Emma Whitfield , Becky White , Matthew E. Barclay , Meena Rafiq , Cristina Renzi , Brian Rous , Spiros Denaxas , Georgios Lyratzopoulos

Background

Differences in the recording of cancer case status and diagnosis date have been observed between cancer registry (CR) – the reference standard – and electronic health records (EHRs); such differences may affect estimates of cancer risk or misclassify diagnostic pathways. This study aims to quantify differences in recording of case status and date of cancer diagnosis between cancer registry and EHRs.

Methods

Linked primary care (Clinical Practice Research Datalink (CPRD)), secondary care (Hospital Episode Statistics (HES)) and national Cancer Registry (CR) data, were used to identify 14,301 patients with a recorded diagnosis of brain, colon, lung, ovarian, or pancreatic cancer between 1999 and 2018. Agreement in case status between datasets, differences in recorded diagnosis dates, and change in agreement over time were investigated for each cancer site.

Results

Between 84 % (ovary) to 92 % (colon) of diagnoses in cancer registry were also recorded in combined CPRD-HES data. Agreement with cancer registry was slightly lower in HES (78 % (ovary) to 86 % (colon)) and CPRD (61 % (ovary, pancreas) to 72 % (brain)). The proportion of CPRD-HES diagnoses confirmed in CR varied by cancer site (50 % (brain) to 86 % (lung)). Agreement between CR and HES was relatively stable within cancer sites over time. Concordance between CR and CPRD was more heterogeneous between cancer sites and over time. Best agreement in diagnosis date was observed between CR and HES (median difference 0 or 1 days, all cancer sites).

Conclusion

Agreement between CR and EHR data is heterogeneous across cancer sites. Concordance does not appear to have improved over time. Combined data from primary and secondary care may be sufficient to approximate case status in CR in some circumstances, but the date we consider to represent the diagnosis may impact study outcomes.

{"title":"Differences in recording of cancer diagnosis between datasets in England: A population-based study of linked cancer registration, hospital, and primary care data","authors":"Emma Whitfield , Becky White , Matthew E. Barclay , Meena Rafiq , Cristina Renzi , Brian Rous , Spiros Denaxas , Georgios Lyratzopoulos","doi":"10.1016/j.canep.2024.102703","DOIUrl":"10.1016/j.canep.2024.102703","url":null,"abstract":"<div><h3>Background</h3><div>Differences in the recording of cancer case status and diagnosis date have been observed between cancer registry (CR) – the reference standard – and electronic health records (EHRs); such differences may affect estimates of cancer risk or misclassify diagnostic pathways. This study aims to quantify differences in recording of case status and date of cancer diagnosis between cancer registry and EHRs.</div></div><div><h3>Methods</h3><div>Linked primary care (Clinical Practice Research Datalink (CPRD)), secondary care (Hospital Episode Statistics (HES)) and national Cancer Registry (CR) data, were used to identify 14,301 patients with a recorded diagnosis of brain, colon, lung, ovarian, or pancreatic cancer between 1999 and 2018. Agreement in case status between datasets, differences in recorded diagnosis dates, and change in agreement over time were investigated for each cancer site.</div></div><div><h3>Results</h3><div>Between 84 % (ovary) to 92 % (colon) of diagnoses in cancer registry were also recorded in combined CPRD-HES data. Agreement with cancer registry was slightly lower in HES (78 % (ovary) to 86 % (colon)) and CPRD (61 % (ovary, pancreas) to 72 % (brain)). The proportion of CPRD-HES diagnoses confirmed in CR varied by cancer site (50 % (brain) to 86 % (lung)). Agreement between CR and HES was relatively stable within cancer sites over time. Concordance between CR and CPRD was more heterogeneous between cancer sites and over time. Best agreement in diagnosis date was observed between CR and HES (median difference 0 or 1 days, all cancer sites).</div></div><div><h3>Conclusion</h3><div>Agreement between CR and EHR data is heterogeneous across cancer sites. Concordance does not appear to have improved over time. Combined data from primary and secondary care may be sufficient to approximate case status in CR in some circumstances, but the date we consider to represent the diagnosis may impact study outcomes.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102703"},"PeriodicalIF":2.4,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142743279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in incidence, mortality and survival of gastric cancer in Xiamen, China from 2011 to 2020: A population-based study

IF 2.4 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2024-11-29 DOI: 10.1016/j.canep.2024.102718

Ahua Wu , Zhinan Guo , Yilan Lin, Jiahuang Chi, Yanqi Lan, Qun Lou, Haixia Zhang, Youlan Chen

Background

Gastric cancer remains one of the most common cancers and the leading cause of death in China. This study aims to describe the incidence, mortality, survival rates, and their changing trends of gastric cancer in Xiamen, China from 2011 to 2020.

Methods

Population-based cancer registry data were used to calculate the incidence, mortality, and survival rates of gastric cancer. The study population consisted of gastric cancer patients diagnosed from January 1, 2011, to December 31, 2020, and followed up until September 30, 2023. The relative survival of gastric cancer was calculated using period methods. The change in trends was analyzed using Joinpoint regression.

Results

From 2011–2020, a total of 4716 new cases of gastric cancer and 3520 related deaths were reported. The crude incidence rate and age-standardized incidence rate (ASIR) were 21.82/100,000 and 16.74/100,000. The crude mortality rate and age-standardized mortality rate (ASMR) were 16.29/100,000 and 12.30/100,000. The ASIR and ASMR in males (ASIR: 24.71/100,000, ASMR: 18.75/100,000) were both more than those in females (ASIR: 9.6/100,000, ASMR: 6.55/100,000). The observed 5-year survival rate was 25.83 %, with an age standardized survival of 27.60 %. The incidence and mortality of gastric cancer showed a decreasing trend, and the 5-year ARS between 2016 and 2020 (30.03 %, 95 %CI: 28.07–32.12 %) was higher than between 2011 and 2015 ( 24.79 %, 95 %CI: 22.53–27.27 %). Furthermore, the survival rate decreased with increasing age.

Conclusions

From 2011–2020, the incidence and mortality of gastric cancer in Xiamen City have shown a decreasing trend, and the survival rate has significantly improved. Despite improved survival, the 5-year ARS remains low.

{"title":"Trends in incidence, mortality and survival of gastric cancer in Xiamen, China from 2011 to 2020: A population-based study","authors":"Ahua Wu , Zhinan Guo , Yilan Lin, Jiahuang Chi, Yanqi Lan, Qun Lou, Haixia Zhang, Youlan Chen","doi":"10.1016/j.canep.2024.102718","DOIUrl":"10.1016/j.canep.2024.102718","url":null,"abstract":"<div><h3>Background</h3><div>Gastric cancer remains one of the most common cancers and the leading cause of death in China. This study aims to describe the incidence, mortality, survival rates, and their changing trends of gastric cancer in Xiamen, China from 2011 to 2020.</div></div><div><h3>Methods</h3><div>Population-based cancer registry data were used to calculate the incidence, mortality, and survival rates of gastric cancer. The study population consisted of gastric cancer patients diagnosed from January 1, 2011, to December 31, 2020, and followed up until September 30, 2023. The relative survival of gastric cancer was calculated using period methods. The change in trends was analyzed using Joinpoint regression.</div></div><div><h3>Results</h3><div>From 2011–2020, a total of 4716 new cases of gastric cancer and 3520 related deaths were reported. The crude incidence rate and age-standardized incidence rate (ASIR) were 21.82/100,000 and 16.74/100,000. The crude mortality rate and age-standardized mortality rate (ASMR) were 16.29/100,000 and 12.30/100,000. The ASIR and ASMR in males (ASIR: 24.71/100,000, ASMR: 18.75/100,000) were both more than those in females (ASIR: 9.6/100,000, ASMR: 6.55/100,000). The observed 5-year survival rate was 25.83 %, with an age standardized survival of 27.60 %. The incidence and mortality of gastric cancer showed a decreasing trend, and the 5-year ARS between 2016 and 2020 (30.03 %, 95 %CI: 28.07–32.12 %) was higher than between 2011 and 2015 ( 24.79 %, 95 %CI: 22.53–27.27 %). Furthermore, the survival rate decreased with increasing age.</div></div><div><h3>Conclusions</h3><div>From 2011–2020, the incidence and mortality of gastric cancer in Xiamen City have shown a decreasing trend, and the survival rate has significantly improved. Despite improved survival, the 5-year ARS remains low.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102718"},"PeriodicalIF":2.4,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142743280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updated cancer burden in oldest old: A population-based study using 2022 Globocan estimates. 高龄老人的最新癌症负担：利用 2022 年 Globocan 估计数据进行的人口研究。

IF 2.4 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2024-11-26 DOI: 10.1016/j.canep.2024.102716

Richa Shah, Nicolò Matteo Luca Battisti, Etienne Brain, Freddy H R Gnangnon, Ravindran Kanesvaran, Supriya Mohile, Vanita Noronha, Martine Puts, Enrique Soto-Perez-de-Celis, Sophie Pilleron

Background: The global population aged 80 years or older is expected to triple by 2050, leading to an increased cancer burden in the oldest population. This study describes the estimated cancer incidence and mortality in 2022 and projections for 2050 in the oldest old, analyzed globally and by world regions and World Bank income levels, for all sexes combined, as well as separately for males and females.

Methods: Using GLOBOCAN 2022 estimates, we reported the estimated number of new cancer cases (excluding non-melanoma skin cancers), deaths, and truncated age-standardized incidence (ASIR) and mortality rates (ASMR) (per 100,000 individuals aged 80 years or older). We also presented the top five cancers by cases and deaths. Additionally, we projected the number of new cancer cases and deaths for each region in 2050, assuming no change in cancer incidence and death rates.

Result: In 2022, an estimated 2.6 million new cancer cases (14 % of all cancer cases) and 2.1 million cancer deaths (22 % of all cancer deaths) occurred in the oldest old, with regional variations. Globally, lung, colorectal, and prostate cancers were the most common cancers diagnosed and leading causes of cancer death. ASIR ranged from 987 in Africa to 2044 per 100,000 in Northern America while ASMR ranged from 981 in Africa to 1769 per 100,000 in Oceania. In 2050, an estimated 7.4 million new cancer cases and 6 million cancer deaths are expected. The greatest increases are anticipated in China, India, and Africa, with increases exceeding 200 % compared to 2022 estimates.

Conclusion: The growing cancer burden among the oldest old poses significant challenges to global healthcare systems, necessitating resource-tailored adaptations. These findings call for the inclusion of the oldest old in the development and implementation of cancer control policies and a better representation in cancer research.

背景：预计到 2050 年，全球 80 岁或以上的人口将增加两倍，从而导致高龄人口的癌症负担加重。本研究描述了 2022 年高龄老年人癌症发病率和死亡率的估计值以及 2050 年的预测值，并按全球、世界各地区和世界银行收入水平进行了分析，包括所有性别以及男性和女性：我们利用 GLOBOCAN 2022 估计数据，报告了癌症新病例（不包括非黑色素瘤皮肤癌）、死亡人数、截断年龄标准化发病率（ASIR）和死亡率（ASMR）（每 10 万名 80 岁或以上老年人）的估计数字。我们还介绍了发病率和死亡率最高的五种癌症。此外，假设癌症发病率和死亡率不变，我们还预测了 2050 年每个地区新增癌症病例和死亡人数：2022 年，估计有 260 万癌症新病例（占癌症病例总数的 14%）和 210 万癌症死亡病例（占癌症死亡病例总数的 22%）发生在最年长的人群中，但各地区之间存在差异。在全球范围内，肺癌、结肠直肠癌和前列腺癌是最常见的确诊癌症，也是癌症死亡的主要原因。ASIR 从非洲的每 10 万人 987 例到北美洲的 2044 例不等，而 ASMR 则从非洲的每 10 万人 981 例到大洋洲的 1769 例不等。2050 年，预计将新增 740 万癌症病例和 600 万癌症死亡病例。预计中国、印度和非洲的增幅最大，与 2022 年的估计值相比，增幅超过 200%：高龄老人癌症负担日益加重，给全球医疗保健系统带来了重大挑战，需要根据资源情况进行调整。这些研究结果呼吁将高龄老人纳入癌症控制政策的制定和实施过程中，并让他们在癌症研究中有更好的代表性。

{"title":"Updated cancer burden in oldest old: A population-based study using 2022 Globocan estimates.","authors":"Richa Shah, Nicolò Matteo Luca Battisti, Etienne Brain, Freddy H R Gnangnon, Ravindran Kanesvaran, Supriya Mohile, Vanita Noronha, Martine Puts, Enrique Soto-Perez-de-Celis, Sophie Pilleron","doi":"10.1016/j.canep.2024.102716","DOIUrl":"https://doi.org/10.1016/j.canep.2024.102716","url":null,"abstract":"<p><strong>Background: </strong>The global population aged 80 years or older is expected to triple by 2050, leading to an increased cancer burden in the oldest population. This study describes the estimated cancer incidence and mortality in 2022 and projections for 2050 in the oldest old, analyzed globally and by world regions and World Bank income levels, for all sexes combined, as well as separately for males and females.</p><p><strong>Methods: </strong>Using GLOBOCAN 2022 estimates, we reported the estimated number of new cancer cases (excluding non-melanoma skin cancers), deaths, and truncated age-standardized incidence (ASIR) and mortality rates (ASMR) (per 100,000 individuals aged 80 years or older). We also presented the top five cancers by cases and deaths. Additionally, we projected the number of new cancer cases and deaths for each region in 2050, assuming no change in cancer incidence and death rates.</p><p><strong>Result: </strong>In 2022, an estimated 2.6 million new cancer cases (14 % of all cancer cases) and 2.1 million cancer deaths (22 % of all cancer deaths) occurred in the oldest old, with regional variations. Globally, lung, colorectal, and prostate cancers were the most common cancers diagnosed and leading causes of cancer death. ASIR ranged from 987 in Africa to 2044 per 100,000 in Northern America while ASMR ranged from 981 in Africa to 1769 per 100,000 in Oceania. In 2050, an estimated 7.4 million new cancer cases and 6 million cancer deaths are expected. The greatest increases are anticipated in China, India, and Africa, with increases exceeding 200 % compared to 2022 estimates.</p><p><strong>Conclusion: </strong>The growing cancer burden among the oldest old poses significant challenges to global healthcare systems, necessitating resource-tailored adaptations. These findings call for the inclusion of the oldest old in the development and implementation of cancer control policies and a better representation in cancer research.</p>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":" ","pages":"102716"},"PeriodicalIF":2.4,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Years of life lost due to cancer in Ecuador 厄瓜多尔因癌症而损失的生命年数

IF 2.4 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2024-11-25 DOI: 10.1016/j.canep.2024.102717

Kevin Ricardo Espinosa-Yépez

Background

Cancer is the leading cause of death worldwide. In the Americas, it is also one of the leading causes of death. In Ecuador, studies on the burden of disease are limited and none analyze or estimate the burden of all types of cancer in a single study. Therefore, the aim of this study is to estimate the years of life lost prematurely due to cancer in Ecuador from 2014 to 2022.

Methods

Cross-sectional observational analysis study. The databases of general deaths from the years 2014 to 2022, population projections from 2014 to 2021 and the population census for the year 2022 of the Republic of Ecuador were used. Deaths registered with ICD-10 code C00-C96 were included as deaths from cancer. The mortality rate and years of life lost prematurely due to cancer were estimated, considering the life tables of the Coale-Demeny West model and a standard time discount of 3 % was implemented without weighting by age.

Results

An increase in mortality and premature years of life lost was observed in the period 2014–2019, but in 2020 a reduction in mortality was seen in several types of cancer. In 2021 and 2022 mortality increased again, reaching the maximum peak of mortality and premature years of life lost in the entire study. Approximately 1,3 million years of life lost prematurely due to cancer were estimated. The types of cancer with the greatest number of years of life lost prematurely were malignant tumors of the stomach (188.180), uterus (117.142), which include both uterine cancer and cervical cancer, and leukemia (107.440). In men, in descending order, these were tumors of the stomach (101.112), prostate (67.624) and leukemia (55.654), while in women, these were malignant tumors of the uterus (117.142), breast (100.217) and stomach (87.067).

Conclusions

The results of this study provide a broader basis for debate on public health policies, efficient allocation of resources, and enable monitoring of cancer and prevention strategies over time.

背景癌症是导致全球死亡的主要原因。在美洲，癌症也是导致死亡的主要原因之一。在厄瓜多尔，关于疾病负担的研究非常有限，没有一项研究能在一项研究中分析或估计所有类型癌症的负担。因此，本研究旨在估算 2014 年至 2022 年厄瓜多尔因癌症而过早丧失的生命年数。研究使用了厄瓜多尔共和国 2014 年至 2022 年的普通死亡数据库、2014 年至 2021 年的人口预测以及 2022 年的人口普查。ICD-10代码为C00-C96的死亡病例被列为癌症死亡病例。根据 Coale-Demeny West 模型的生命表估算了死亡率和因癌症过早丧失的生命年数，并采用了 3% 的标准时间折扣，未按年龄加权。2021 年和 2022 年，死亡率再次上升，达到了整个研究中死亡率和过早死亡年数的最高峰。据估计，因癌症而过早丧失的生命年数约为 130 万年。过早丧失生命年数最多的癌症类型是胃部恶性肿瘤（188 180）、子宫（117 142）（包括子宫癌和宫颈癌）和白血病（107 440）。在男性中，从高到低依次为胃肿瘤（101.112）、前列腺肿瘤（67.624）和白血病（55.654）；在女性中，从高到低依次为子宫恶性肿瘤（117.142）、乳腺癌（100.217）和胃肿瘤（87.067）。

{"title":"Years of life lost due to cancer in Ecuador","authors":"Kevin Ricardo Espinosa-Yépez","doi":"10.1016/j.canep.2024.102717","DOIUrl":"10.1016/j.canep.2024.102717","url":null,"abstract":"<div><h3>Background</h3><div>Cancer is the leading cause of death worldwide. In the Americas, it is also one of the leading causes of death. In Ecuador, studies on the burden of disease are limited and none analyze or estimate the burden of all types of cancer in a single study. Therefore, the aim of this study is to estimate the years of life lost prematurely due to cancer in Ecuador from 2014 to 2022.</div></div><div><h3>Methods</h3><div>Cross-sectional observational analysis study. The databases of general deaths from the years 2014 to 2022, population projections from 2014 to 2021 and the population census for the year 2022 of the Republic of Ecuador were used. Deaths registered with ICD-10 code C00-C96 were included as deaths from cancer. The mortality rate and years of life lost prematurely due to cancer were estimated, considering the life tables of the Coale-Demeny West model and a standard time discount of 3 % was implemented without weighting by age.</div></div><div><h3>Results</h3><div>An increase in mortality and premature years of life lost was observed in the period 2014–2019, but in 2020 a reduction in mortality was seen in several types of cancer. In 2021 and 2022 mortality increased again, reaching the maximum peak of mortality and premature years of life lost in the entire study. Approximately 1,3 million years of life lost prematurely due to cancer were estimated. The types of cancer with the greatest number of years of life lost prematurely were malignant tumors of the stomach (188.180), uterus (117.142), which include both uterine cancer and cervical cancer, and leukemia (107.440). In men, in descending order, these were tumors of the stomach (101.112), prostate (67.624) and leukemia (55.654), while in women, these were malignant tumors of the uterus (117.142), breast (100.217) and stomach (87.067).</div></div><div><h3>Conclusions</h3><div>The results of this study provide a broader basis for debate on public health policies, efficient allocation of resources, and enable monitoring of cancer and prevention strategies over time.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102717"},"PeriodicalIF":2.4,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142704268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in incidence and survival of the four most common cancers by stage at diagnosis in Cyprus: A population-based study from 2004 to 2017 塞浦路斯按诊断阶段划分的四种最常见癌症的发病率和生存率趋势：2004 年至 2017 年基于人口的研究

IF 2.4 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2024-11-23 DOI: 10.1016/j.canep.2024.102704

Christiana A. Demetriou , Constantinos Koshiaris , Olivia A. Cory , Constantina Constantinou , Ourania Kolokotroni , Yiola Marcou , Demetris Papamichael , Haris Charalambous , Dimitrios Vomvas , Anna Demetriou , Vasos Scoutellas , Annalisa Quattrocchi

Background

Breast, colorectal, lung and prostate cancers are the most frequent malignancies in Cyprus. This study estimated the incidence rate and 5-year net survival (NS) trends for these cancers, by sex, age, and tumor stage at diagnosis.

Methods

We analyzed data from the Cyprus Cancer Registry for adults diagnosed between 2004 and 2017, with follow-up until 2019. Tumor stage was classified into localized, regional, distant and unknown categories. We estimated the annual percentage change (APC) in incidence rates using Joinpoint regression. NS was estimated using flexible parametric models, adjusting for sex, age, stage and period of diagnosis. Multiple imputation was used to address unknown cancer stage.

Results

During 2004–2017, the incidence significantly increased for breast and lung cancer (APC: 1.1 % and 2.6 %, respectively), mainly among the elderly (70 +). A decreasing trend was identified for prostate cancer only among individuals aged 80 +. No temporal variations were identified for colorectal cancer incidence.

A positive time trend was identified for localized breast cancer between 2006 and 2017 (APC: 2.8 %). Conversely, a significant increase was noted at more advanced stages for lung (APC_distant: 4.1 %) and prostate (APC_regional: 7.6 %) cancers.

NS improved for all cancers, ranging between 80 % and 90 % for regional and all stages of breast cancer, localized colorectal cancer, and all stages of prostate cancer, surpassing 95 % for localized breast cancer, localized and regional prostate cancer.

Conclusion

The study observed increased (breast and lung) or stable (colorectal and prostate) cancer incidence and substantial improvements in 5-years NS trends for all cancer types, despite differences by sex and stage. Efforts should be intensified to reduce incidence by addressing cancer risk factors, and to improve survival by implementing and increasing the uptake of screening programs.

背景乳腺癌、结直肠癌、肺癌和前列腺癌是塞浦路斯最常见的恶性肿瘤。这项研究按性别、年龄和诊断时的肿瘤分期估算了这些癌症的发病率和 5 年净生存率（NS）趋势。肿瘤分期分为局部、区域、远处和未知类别。我们使用Joinpoint回归估算了发病率的年度百分比变化（APC）。NS采用灵活的参数模型进行估算，并根据性别、年龄、分期和诊断时间进行调整。结果2004-2017年间，乳腺癌和肺癌的发病率显著上升（APC：分别为1.1%和2.6%），主要发生在老年人（70岁以上）中。只有在 80 岁以上的人群中，前列腺癌的发病率呈下降趋势。2006 年至 2017 年间，局部乳腺癌的发病率呈上升趋势（APC：2.8%）。所有癌症的 NS 均有所改善，区域性和所有阶段的乳腺癌、局部性结直肠癌以及所有阶段的前列腺癌的 NS 在 80% 至 90% 之间，局部性乳腺癌、局部性和区域性前列腺癌的 NS 超过 95%。结论该研究观察到，尽管性别和分期不同，但所有癌症类型的发病率（乳腺癌和肺癌）均有所上升或保持稳定（结肠直肠癌和前列腺癌），5 年 NS 趋势也有显著改善。应加强努力，通过应对癌症风险因素来降低发病率，并通过实施筛查计划和提高筛查率来提高生存率。

{"title":"Trends in incidence and survival of the four most common cancers by stage at diagnosis in Cyprus: A population-based study from 2004 to 2017","authors":"Christiana A. Demetriou , Constantinos Koshiaris , Olivia A. Cory , Constantina Constantinou , Ourania Kolokotroni , Yiola Marcou , Demetris Papamichael , Haris Charalambous , Dimitrios Vomvas , Anna Demetriou , Vasos Scoutellas , Annalisa Quattrocchi","doi":"10.1016/j.canep.2024.102704","DOIUrl":"10.1016/j.canep.2024.102704","url":null,"abstract":"<div><h3>Background</h3><div>Breast, colorectal, lung and prostate cancers are the most frequent malignancies in Cyprus. This study estimated the incidence rate and 5-year net survival (NS) trends for these cancers, by sex, age, and tumor stage at diagnosis.</div></div><div><h3>Methods</h3><div>We analyzed data from the Cyprus Cancer Registry for adults diagnosed between 2004 and 2017, with follow-up until 2019. Tumor stage was classified into localized, regional, distant and unknown categories. We estimated the annual percentage change (APC) in incidence rates using Joinpoint regression. NS was estimated using flexible parametric models, adjusting for sex, age, stage and period of diagnosis. Multiple imputation was used to address unknown cancer stage.</div></div><div><h3>Results</h3><div>During 2004–2017, the incidence significantly increased for breast and lung cancer (APC: 1.1 % and 2.6 %, respectively), mainly among the elderly (70 +). A decreasing trend was identified for prostate cancer only among individuals aged 80 +. No temporal variations were identified for colorectal cancer incidence.</div><div>A positive time trend was identified for localized breast cancer between 2006 and 2017 (APC: 2.8 %). Conversely, a significant increase was noted at more advanced stages for lung (APC<sub>distant</sub>: 4.1 %) and prostate (APC<sub>regional</sub>: 7.6 %) cancers.</div><div>NS improved for all cancers, ranging between 80 % and 90 % for regional and all stages of breast cancer, localized colorectal cancer, and all stages of prostate cancer, surpassing 95 % for localized breast cancer, localized and regional prostate cancer.</div></div><div><h3>Conclusion</h3><div>The study observed increased (breast and lung) or stable (colorectal and prostate) cancer incidence and substantial improvements in 5-years NS trends for all cancer types, despite differences by sex and stage. Efforts should be intensified to reduce incidence by addressing cancer risk factors, and to improve survival by implementing and increasing the uptake of screening programs.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102704"},"PeriodicalIF":2.4,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142704269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Measuring healthy life expectancy and determinants of poor perceived health: A population-based study among a subset of rare and common cancer survivors 衡量健康预期寿命和不良健康感知的决定因素：一项针对罕见和常见癌症幸存者的人群研究。

IF 2.4 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2024-11-22 DOI: 10.1016/j.canep.2024.102706

Eline de Heus , Saskia F.A. Duijts , Jan Maarten van der Zwan , Carla M.L. van Herpen , Matthias A.W. Merkx , Mark J. Rutherford , Isabelle Soerjomataram

Background

As the survival proportions for rare cancers are on average worse than for common cancers, assessing the expected remaining life years in good health becomes highly relevant. This study aimed to estimate the healthy life expectancy (HLE) of a subset of rare and common cancer survivors, and to assess the determinants of poor perceived health in rare cancer survivors.

Methods

To calculate HLE, survival data from the population-based Netherlands Cancer Registry of survivors of a rare cancer (i.e., ovarian cancer, thyroid cancer, Hodgkin lymphoma, non-Hodgkin lymphoma) (n=21,376) and a common cancer (i.e., colorectal cancer (CRC)) (n=76,949) were combined with quality of life (QoL) data from the PROFILES registry on a random sample of the rare (n=1025) and common cancer (n=2400) survivors. A flexible parametric relative survival model was used to estimate life expectancy (LE) and years of life lost, and multivariate logistic regression was applied to determine factors related to reported poor perceived health.

Results

Patients previously diagnosed with a rare cancer had an average LE of 8–36 years and were expected to spend ≥67 % of their remaining life in good health. CRC survivors had an average LE of 10 years with approximately 65 % of their remaining life expected to spend in good health. For all cancer types, those aged ≥65 years or with stage IV had the lowest HLE. Low socioeconomic status, advanced stage, and having received radiotherapy only were important predictors of poor perceived health among rare cancer survivors.

Conclusion

HLE can provide meaningful perspective for patients and practitioners for all cancer types, including rare cancers. Yet, data on QoL for rare cancers should be routinely collected, as such will serve as an indicator for monitoring and improving cancer care, and for enabling HLE measurements in cancer survivors.

背景：由于罕见癌症的平均存活比例低于常见癌症，因此评估健康状况良好的预期剩余寿命就变得非常重要。本研究旨在估算罕见癌症和普通癌症幸存者子集的健康预期寿命（HLE），并评估罕见癌症幸存者健康状况差的决定因素：为了计算 HLE，我们从荷兰癌症登记处收集了罕见癌症（即卵巢癌、甲状腺癌、霍奇金淋巴瘤、非霍奇金淋巴瘤）和常见癌症（即结直肠癌 (CRC)）幸存者的生存数据（21,376 人）、将罕见癌症（1025 人）和常见癌症（2400 人）幸存者的随机抽样数据与 PROFILES 登记处提供的生活质量（QoL）数据相结合。采用灵活的参数相对生存模型来估算预期寿命（LE）和损失的生命年数，并采用多变量逻辑回归来确定与所报告的健康感知不良有关的因素：结果：曾被诊断为罕见癌症的患者的平均预期寿命为 8-36 年，预计其余生中健康状况良好的时间≥67%。CRC 幸存者的平均寿命为 10 年，预计其剩余生命中约 65% 的时间处于健康状态。在所有癌症类型中，年龄≥65 岁或处于 IV 期的患者的健康生活率最低。在罕见癌症幸存者中，社会经济地位低、晚期和只接受过放疗是预测健康状况差的重要因素：HLE可以为包括罕见癌症在内的所有癌症类型的患者和医生提供有意义的视角。然而，罕见癌症的 QoL 数据应常规收集，因为这将作为监测和改善癌症护理的指标，并可用于测量癌症幸存者的 HLE。

{"title":"Measuring healthy life expectancy and determinants of poor perceived health: A population-based study among a subset of rare and common cancer survivors","authors":"Eline de Heus , Saskia F.A. Duijts , Jan Maarten van der Zwan , Carla M.L. van Herpen , Matthias A.W. Merkx , Mark J. Rutherford , Isabelle Soerjomataram","doi":"10.1016/j.canep.2024.102706","DOIUrl":"10.1016/j.canep.2024.102706","url":null,"abstract":"<div><h3>Background</h3><div>As the survival proportions for rare cancers are on average worse than for common cancers, assessing the expected remaining life years in good health becomes highly relevant. This study aimed to estimate the healthy life expectancy (HLE) of a subset of rare and common cancer survivors, and to assess the determinants of poor perceived health in rare cancer survivors.</div></div><div><h3>Methods</h3><div>To calculate HLE, survival data from the population-based Netherlands Cancer Registry of survivors of a rare cancer (i.e., ovarian cancer, thyroid cancer, Hodgkin lymphoma, non-Hodgkin lymphoma) (n=21,376) and a common cancer (i.e., colorectal cancer (CRC)) (n=76,949) were combined with quality of life (QoL) data from the PROFILES registry on a random sample of the rare (n=1025) and common cancer (n=2400) survivors. A flexible parametric relative survival model was used to estimate life expectancy (LE) and years of life lost, and multivariate logistic regression was applied to determine factors related to reported poor perceived health.</div></div><div><h3>Results</h3><div>Patients previously diagnosed with a rare cancer had an average LE of 8–36 years and were expected to spend ≥67 % of their remaining life in good health. CRC survivors had an average LE of 10 years with approximately 65 % of their remaining life expected to spend in good health. For all cancer types, those aged ≥65 years or with stage IV had the lowest HLE. Low socioeconomic status, advanced stage, and having received radiotherapy only were important predictors of poor perceived health among rare cancer survivors.</div></div><div><h3>Conclusion</h3><div>HLE can provide meaningful perspective for patients and practitioners for all cancer types, including rare cancers. Yet, data on QoL for rare cancers should be routinely collected, as such will serve as an indicator for monitoring and improving cancer care, and for enabling HLE measurements in cancer survivors.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102706"},"PeriodicalIF":2.4,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Colorectal cancer survival in Mexico: Leveraging a national health insurance database 墨西哥的结直肠癌存活率：利用全国医疗保险数据库。

IF 2.4 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2024-11-21 DOI: 10.1016/j.canep.2024.102698

Susana Lozano-Esparza , Hugo Rodrigo Sánchez-Blas , Fidel David Huitzil-Meléndez , Mónica Isabel Meneses-Medina , Katherine Van Loon , Michael B. Potter , Alejandro Mohar , Martin Lajous

Purpose

We estimated the 5-year overall, age at diagnosis- and stage-specific colorectal cancer survival in patients treated through their coverage with Seguro Popular.

Methods

We conducted a retrospective study using a dataset that included 1418 colorectal cancer patients covered by Seguro Popular (Mexico’s public health insurance system covering 60 % of the population) between 2013 and 2016. Deaths were identified using the Epidemiologic Death Statistics Subsystem registry, with a specialized algorithm for record linkage. The Kaplan-Meier method was used to estimate overall survival curves and the proportion of patients alive at various follow-up time points. We compared survival curves across subgroups using the log-rank test.

Results

In this study the average age at diagnosis was 56 years with 31.9 % of patients diagnosed before the age of 50. Most cases (78.1 %) were diagnosed in advanced stages (i.e., III and IV), with nearly half of the cases originating in the rectum. The overall 5-year survival was 50 %, with higher survival (74 %) for patients with stage I-II and lower survival for those with stage III (58 %) and IV (33 %). While age at diagnosis was not associated with survival for early-stage colorectal cancer, younger patients with metastatic disease had a worse prognosis compared to older patients.

Conclusion

The 5-year overall colorectal cancer survival was 50 %, with variation by clinical stage. Almost 80 % of the population was diagnosed with advanced stages, underscoring the need for screening programs. Younger patients with metastatic disease exhibited a worse prognosis, highlighting the need for targeted interventions.

目的：我们估算了通过参加 Seguro Popular 保险接受治疗的结直肠癌患者的 5 年总生存率、诊断年龄和分期生存率：我们使用一个数据集开展了一项回顾性研究，该数据集包括 2013 年至 2016 年期间由 Seguro Popular（墨西哥的公共医疗保险系统，覆盖 60% 的人口）承保的 1418 名结直肠癌患者。死亡病例通过流行病学死亡统计子系统登记处进行确认，并采用专门的算法进行记录链接。我们采用卡普兰-梅耶法估算了总体生存曲线和不同随访时间点的存活患者比例。我们使用对数秩检验比较了不同亚组的生存曲线：本研究中，确诊患者的平均年龄为 56 岁，其中 31.9% 的患者在 50 岁之前确诊。大多数病例（78.1%）被诊断为晚期（即 III 期和 IV 期），近一半的病例起源于直肠。总的 5 年存活率为 50%，其中 I-II 期患者的存活率较高（74%），而 III 期（58%）和 IV 期（33%）患者的存活率较低。虽然诊断时的年龄与早期结直肠癌患者的生存率无关，但与年龄较大的患者相比，患有转移性疾病的年轻患者预后较差：结论：结直肠癌患者的 5 年总生存率为 50%，不同临床阶段的生存率有所不同。近 80% 的患者被确诊为晚期，这凸显了筛查计划的必要性。患有转移性疾病的年轻患者预后较差，这说明有必要采取有针对性的干预措施。

{"title":"Colorectal cancer survival in Mexico: Leveraging a national health insurance database","authors":"Susana Lozano-Esparza , Hugo Rodrigo Sánchez-Blas , Fidel David Huitzil-Meléndez , Mónica Isabel Meneses-Medina , Katherine Van Loon , Michael B. Potter , Alejandro Mohar , Martin Lajous","doi":"10.1016/j.canep.2024.102698","DOIUrl":"10.1016/j.canep.2024.102698","url":null,"abstract":"<div><h3>Purpose</h3><div>We estimated the 5-year overall, age at diagnosis- and stage-specific colorectal cancer survival in patients treated through their coverage with <em>Seguro Popular</em>.</div></div><div><h3>Methods</h3><div>We conducted a retrospective study using a dataset that included 1418 colorectal cancer patients covered by <em>Seguro Popular</em> (Mexico’s public health insurance system covering 60 % of the population) between 2013 and 2016. Deaths were identified using the Epidemiologic Death Statistics Subsystem registry, with a specialized algorithm for record linkage. The Kaplan-Meier method was used to estimate overall survival curves and the proportion of patients alive at various follow-up time points. We compared survival curves across subgroups using the log-rank test.</div></div><div><h3>Results</h3><div>In this study the average age at diagnosis was 56 years with 31.9 % of patients diagnosed before the age of 50. Most cases (78.1 %) were diagnosed in advanced stages (i.e., III and IV), with nearly half of the cases originating in the rectum. The overall 5-year survival was 50 %, with higher survival (74 %) for patients with stage I-II and lower survival for those with stage III (58 %) and IV (33 %). While age at diagnosis was not associated with survival for early-stage colorectal cancer, younger patients with metastatic disease had a worse prognosis compared to older patients.</div></div><div><h3>Conclusion</h3><div>The 5-year overall colorectal cancer survival was 50 %, with variation by clinical stage. Almost 80 % of the population was diagnosed with advanced stages, underscoring the need for screening programs. Younger patients with metastatic disease exhibited a worse prognosis, highlighting the need for targeted interventions.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102698"},"PeriodicalIF":2.4,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rurality and pediatric cancer survival in the United States: An analysis of SEER data from 2000 to 2021 美国乡村地区与儿童癌症存活率：对 2000 年至 2021 年 SEER 数据的分析。

IF 2.4 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2024-11-18 DOI: 10.1016/j.canep.2024.102705

Emma Hymel , Hong Li , Gary L. Cochran , Kendra L. Ratnapradipa , Krishtee Napit , Josiane Kabayundo , Don W. Coulter , Jenna Allison , Edward S. Peters , Shinobu Watanabe-Galloway

Background

Cancer is the leading cause of death by disease among children in the United States. Residing in rural areas may impact cancer outcomes as rural areas tend to have fewer available healthcare resources. Few population-based studies have investigated rural/urban disparities in pediatric cancer outcomes. The objective of this study was to examine rural/urban differences in (1) five-year relative survival and (2) cancer-specific survival among children in the United States.

Methods

The study is a population-based longitudinal study using data from the Surveillance, Epidemiology, and End Results (SEER) 17 registries database (2000–2021). We included data for individuals aged 0–19 with a first primary malignant cancer diagnosed from 2000 to 2016. Rurality was measured by Rural-Urban Continuum Codes (RUCCs). Five-year relative survival rates, Kaplan-Meier curves, and Cox regression analysis were used to determine the differences in pediatric cancer survivorship between rural and urban areas.

Results

Both five-year relative survival rates and log-rank tests of survival probabilities over time by rurality showed no statistically significant difference between individuals living in urban versus rural counties. However, after adjusting for age, sex, race/ethnicity, cancer type, median household income, and region, children diagnosed in rural counties had a 9 % higher risk of death compared to children diagnosed in urban counties (95 % CI 1.02–1.17), with the highest increased risk observed for children with retinoblastoma (aHR: 6.12, 95 % CI 2.01–18.59). A higher increased risk of death was observed for children living in the most rural counties (aHR: 1.18, 95 % CI 1.07–1.32).

Conclusion

In this study, residing in rural areas was associated with an increased risk of death from pediatric cancer, especially for children residing in rural areas not adjacent to urban areas. Our findings warrant further investigation to determine the rural/urban disparities in pediatric cancer outcomes and to develop interventions to deliver high-quality cancer care to rural children.

背景：癌症是美国儿童因病死亡的主要原因。居住在农村地区可能会影响癌症的治疗效果，因为农村地区可用的医疗资源往往较少。很少有基于人群的研究调查了儿科癌症结果的城乡差异。本研究旨在探讨美国农村/城市儿童在（1）五年相对生存率和（2）癌症特异性生存率方面的差异：本研究是一项基于人群的纵向研究，使用的数据来自监测、流行病学和最终结果（SEER）的 17 个登记数据库（2000-2021 年）。我们纳入了 2000 年至 2016 年期间首次确诊为原发性恶性肿瘤的 0-19 岁人群的数据。农村地区通过农村-城市连续编码（RUCCs）来衡量。采用五年相对生存率、Kaplan-Meier曲线和Cox回归分析来确定城乡之间儿科癌症生存率的差异：结果：五年相对存活率和农村地区存活概率的对数秩检验均显示，生活在城市和农村地区的个体之间没有显著的统计学差异。然而，在对年龄、性别、种族/民族、癌症类型、家庭收入中位数和地区进行调整后，农村地区确诊儿童的死亡风险比城市地区确诊儿童高 9%（95 % CI 1.02-1.17），其中视网膜母细胞瘤患儿的死亡风险最高（aHR：6.12，95 % CI 2.01-18.59）。居住在最偏远农村地区的儿童的死亡风险更高（aHR：1.18，95 % CI 1.07-1.32）：在这项研究中，居住在农村地区与儿童癌症死亡风险增加有关，尤其是居住在不毗邻城市地区的农村地区的儿童。我们的研究结果值得进一步调查，以确定儿科癌症结果的城乡差异，并制定干预措施，为农村儿童提供高质量的癌症治疗。

{"title":"Rurality and pediatric cancer survival in the United States: An analysis of SEER data from 2000 to 2021","authors":"Emma Hymel , Hong Li , Gary L. Cochran , Kendra L. Ratnapradipa , Krishtee Napit , Josiane Kabayundo , Don W. Coulter , Jenna Allison , Edward S. Peters , Shinobu Watanabe-Galloway","doi":"10.1016/j.canep.2024.102705","DOIUrl":"10.1016/j.canep.2024.102705","url":null,"abstract":"<div><h3>Background</h3><div>Cancer is the leading cause of death by disease among children in the United States. Residing in rural areas may impact cancer outcomes as rural areas tend to have fewer available healthcare resources. Few population-based studies have investigated rural/urban disparities in pediatric cancer outcomes. The objective of this study was to examine rural/urban differences in (1) five-year relative survival and (2) cancer-specific survival among children in the United States.</div></div><div><h3>Methods</h3><div>The study is a population-based longitudinal study using data from the Surveillance, Epidemiology, and End Results (SEER) 17 registries database (2000–2021). We included data for individuals aged 0–19 with a first primary malignant cancer diagnosed from 2000 to 2016. Rurality was measured by Rural-Urban Continuum Codes (RUCCs). Five-year relative survival rates, Kaplan-Meier curves, and Cox regression analysis were used to determine the differences in pediatric cancer survivorship between rural and urban areas.</div></div><div><h3>Results</h3><div>Both five-year relative survival rates and log-rank tests of survival probabilities over time by rurality showed no statistically significant difference between individuals living in urban versus rural counties. However, after adjusting for age, sex, race/ethnicity, cancer type, median household income, and region, children diagnosed in rural counties had a 9 % higher risk of death compared to children diagnosed in urban counties (95 % CI 1.02–1.17), with the highest increased risk observed for children with retinoblastoma (aHR: 6.12, 95 % CI 2.01–18.59). A higher increased risk of death was observed for children living in the most rural counties (aHR: 1.18, 95 % CI 1.07–1.32).</div></div><div><h3>Conclusion</h3><div>In this study, residing in rural areas was associated with an increased risk of death from pediatric cancer, especially for children residing in rural areas not adjacent to urban areas. Our findings warrant further investigation to determine the rural/urban disparities in pediatric cancer outcomes and to develop interventions to deliver high-quality cancer care to rural children.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102705"},"PeriodicalIF":2.4,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN 2022 年全球肺癌负担及到 2050 年的预测：来自 GLOBOCAN 的发病率和死亡率估算。

IF 2.4 3区医学 Q3 ONCOLOGY

Cancer Epidemiology

Pub Date : 2024-11-13 DOI: 10.1016/j.canep.2024.102693

Jialin Zhou , Ying Xu , Jianmin Liu , Lili Feng , Jinming Yu , Dawei Chen

Background

Lung cancer continues to pose a serious global public health challenge. Timely evidence on the global epidemiological profile of the disease is crucial to facilitate the implementation to lung cancer control efforts. This study provides updated global estimates for lung cancer incidence and mortality in 2022, along with projections for new cases and deaths up to 2050.

Methods

In the population-based study, we extracted data about lung cancer new cases and deaths from GLOBOCAN 2022 database across 185 countries or territories. We analyzed age-standardized rates by sex, country, region, and human development index (HDI). Projected new cases and deaths for 2050 were estimated using global demographic projections.

Results

In 2022, lung cancer stood as the most frequently diagnosed cancer and the primary cause of cancer-related deaths on a global scale with approximately 2.48 million new cases and 1.8 million deaths, respectively. The incidence and mortality rates of lung cancer exhibited disparities in sex and world regions. Furthermore, incidence and mortality rates increasing as HDI increased. If the incidence and mortality rates remain stable as in 2022, the burden of lung cancer is projected to increase to 4·62 million new cases and 3·55 million deaths by 2050.

Conclusions

Lung cancer is the predominant form of cancer and the foremost contributor to cancer-related mortality in 2022 with notable geographical, sex, and socioeconomic disparities.

背景：肺癌继续对全球公共卫生构成严重挑战。及时提供有关该疾病全球流行病学概况的证据对于促进肺癌控制工作的实施至关重要。本研究提供了 2022 年全球肺癌发病率和死亡率的最新估计值，以及到 2050 年新增病例和死亡人数的预测值：在这项基于人群的研究中，我们从 GLOBOCAN 2022 数据库中提取了 185 个国家或地区的肺癌新发病例和死亡病例数据。我们按性别、国家、地区和人类发展指数（HDI）分析了年龄标准化比率。我们还利用全球人口预测估算了 2050 年的新增病例和死亡人数：结果：2022 年，肺癌是全球最常见的癌症，也是癌症相关死亡的主要原因，新增病例和死亡人数分别约为 248 万和 180 万。肺癌的发病率和死亡率在性别和世界地区之间存在差异。此外，发病率和死亡率随着人类发展指数的增加而增加。如果发病率和死亡率与 2022 年保持稳定，预计到 2050 年，肺癌的负担将增加到 4-62 万新发病例和 3-55 万死亡病例：结论：肺癌是癌症的主要形式，也是 2022 年癌症相关死亡率的首要因素，但存在明显的地域、性别和社会经济差异。

{"title":"Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN","authors":"Jialin Zhou , Ying Xu , Jianmin Liu , Lili Feng , Jinming Yu , Dawei Chen","doi":"10.1016/j.canep.2024.102693","DOIUrl":"10.1016/j.canep.2024.102693","url":null,"abstract":"<div><h3>Background</h3><div>Lung cancer continues to pose a serious global public health challenge. Timely evidence on the global epidemiological profile of the disease is crucial to facilitate the implementation to lung cancer control efforts. This study provides updated global estimates for lung cancer incidence and mortality in 2022, along with projections for new cases and deaths up to 2050.</div></div><div><h3>Methods</h3><div>In the population-based study, we extracted data about lung cancer new cases and deaths from GLOBOCAN 2022 database across 185 countries or territories. We analyzed age-standardized rates by sex, country, region, and human development index (HDI). Projected new cases and deaths for 2050 were estimated using global demographic projections.</div></div><div><h3>Results</h3><div>In 2022, lung cancer stood as the most frequently diagnosed cancer and the primary cause of cancer-related deaths on a global scale with approximately 2.48 million new cases and 1.8 million deaths, respectively. The incidence and mortality rates of lung cancer exhibited disparities in sex and world regions. Furthermore, incidence and mortality rates increasing as HDI increased. If the incidence and mortality rates remain stable as in 2022, the burden of lung cancer is projected to increase to 4·62 million new cases and 3·55 million deaths by 2050.</div></div><div><h3>Conclusions</h3><div>Lung cancer is the predominant form of cancer and the foremost contributor to cancer-related mortality in 2022 with notable geographical, sex, and socioeconomic disparities.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102693"},"PeriodicalIF":2.4,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0